Stephen D. Rubin
Providence College(US)GlaxoSmithKline (United States)(US)GlaxoSmithKline (Netherlands)(NL)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Lung Cancer Treatments and Mutations, Brain Metastases and Treatment, Cancer therapeutics and mechanisms, Radiopharmaceutical Chemistry and Applications
Most-Cited Works
- → Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer(2006)3,443 cited
- → Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib(2014)2,622 cited
- → Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer(2009)661 cited
- → A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update(2013)443 cited
- → Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial(2018)340 cited
- → Anastrazole and oral contraceptives: a novel treatment for endometriosis(2005)218 cited